Andere Sprachen Mainz Biomed N.V.

Aktien

A3C6XX

NL0015000LC2

MYNZ

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
0.8181 ^USD	-4.52%		-9.60%	-29.47%

25.04.	Mainz Biomed meldet positive Topline-Ergebnisse einer gepoolten Studie zur Evaluierung neuartiger Mrna-Biomarker und des firmeneigenen Ai-Algorithmus für die Integration in eine klinische FDA-PMA-Studie zur Darmkrebsdiagnostik der nächsten Generation	CI
09.04.	Mainz Biomed N.V. meldet Ergebnis für das Geschäftsjahr zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next-Gen CRC Test	25.04.
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic	25.04.
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel Mrna Biomarkers and Proprietary Ai Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic	25.04.
Mainz Biomed N : Announcement of Annual General Meeting of - Form 6-K	24.04.
Mainz Biomed Reports Full Year 2023 Financial Results	09.04.
Mainz Biomed Reports Full Year 2023 Financial Results	09.04.
Mainz Biomed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	09.04.
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment	19.03.
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment	19.03.
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment	19.03.
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options	18.03.
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options	18.03.
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options	18.03.
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations	12.03.
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations	12.03.
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic	05.03.
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic	05.03.
Mainz Biomed N.V. Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic	05.03.
Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community	27.02.
Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community	27.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Mainz Biomed N.V.

Aktien

A3C6XX

NL0015000LC2

MYNZ

Andere Sprachen

Filter